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Abstract
Background: Young age remains a controversial issue as a prognostic factor in breast cancer.
Debate includes patients from different parts of the world. Almost 50% of patients with breast
cancer seen at the American University of Beirut Medical Center (AUBMC) are below age 50.
Methods: We reviewed 1320 patients seen at AUBMC between 1990 and 2001. We divided them
in three age groups: Below 35, 35–50, and above 50. Data and survival were analyzed using Chi-
square, Cox regression analysis, and Kaplan Meier.
Results: Mean age at presentation was 50.8 years. 107 patients were below age 35, 526 between
35–50 and 687 patients above age 50. Disease stages were as follows: stage I: 14.4%, stage II: 59.9%,
stage III: 20% and stage IV: 5.7%. Hormone receptors were positive in 71.8% of patients below 35,
in 67.6% of patients 35–50 and in 78.3% of patients above 50. Grade of tumor was higher as age at
presentation was lower. More young patients received anthracycline-based adjuvant
chemotherapy. Of hormone receptor-positive patients, 83.8% of those below age 35 years, 87.76%
of those aged 35–50 years, and 91.2% of those aged above 50 years received adjuvant tamoxifen.
The mean follow up time was 3.7 +/- 2.9 years. Time to death was the only variable analyzed for
survival analysis. Excluding stage IV patients, tumor size, lymph node, tumor grade and negative
hormone receptors were inversely proportional to survival. Higher percentage of young patients
at presentation developed metastasis (32.4% of patients below 35, as compared to 22.9% of
patients 35–50 and 22.8% of patients above 50) and had a worse survival. Young age had a negative
impact on survival of patients with positive axillary lymph nodes, and survival of patients with
positive hormonal receptors, but not on survival of patients with negative lymph nodes, or patients
with negative hormonal receptors.
Conclusion: Young age at presentation conferred a worse prognosis in spite of a higher than
expected positive hormone receptor status, more anthracycline-based adjuvant chemotherapy and
equivalent adjuvant tamoxifen hormonal therapy in younger patients. This negative impact on
survival was seen in patients with positive lymph nodes and those with positive hormonal
receptors.
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Background
Breast cancer is the most common female cancer world-
wide and is the second leading cause of cancer mortality
among women in the United States [1]. In Lebanon,
breast cancer is the most frequent malignancy in women
and constitutes about one third of all female cancers [2,3].
While the median age at presentation is around 63 years
in the United States and Western Europe, the median age
at presentation in Lebanon is 48–52 years, similar to Mex-
ico, Saudi Arabia and the palestinians; with an ASR of
46.7 per 100.000 in 1998 [3-8].
Many studies, from many parts of the world, have looked
at the prognostic value of age at diagnosis in patients with
breast cancer [9-19]. In 1994, Swanson, et al, after control-
ling for race, stage and treatment, found that mortality
due to breast cancer is greatest in younger women[9].
Another study of invasive non-metastatic breast cancer in
premenopausal women reported in 1993, young age had
an adverse effect on cancer specific survival and relapse-
free interval[10]. Most of these studies are hospital based
and single institution studies. A recent population-based
study from Switzerland was reported to show that young
women present with larger tumors and more aggressive
tumors but found no effect of age on survival[11]. Studies
from Saudi Arabia and Singapore reported no adverse
effect of young age on survival[12,13]. Factors considered
to play a role in poor prognosis include more aggressive
tumors, higher grades, and negative hormone receptors
status. Recent studies have indicated a higher local relapse
rate in young women with breast cancer treated with
breast-conserving therapy [14-16] which emphasizes the
role of type of treatment received as another factor to be
studied when evaluating the effects of age on prognosis.
We aimed to assess the prognostic value of young age on
the outcome of breast cancer, and to shed more light on
the influence of clinical and pathological characteristics
and treatment modalities on age and prognosis.
Methods
Study cohort
We reviewed the medical records of all 1320 breast cancer
patients seen at the American University of Beirut Medical
Center between 1990 and 2001. Study was approved by
the Institutional Review Board (IRB) of the American Uni-
versity of Beirut Medical Center. Information was col-
lected from the Hospital Inpatient Medical Records
Department, Outpatient Departments, and Radiation
Oncology Department. Additional follow-up information
was collected by phone calls made to patients and/or their
families, where necessary. The details of these interviews
were recorded and the date of interview was used in our
Cox and Kaplan Meier analyses. Fifty-seven patients were
removed from the study because of missing information.
And the remaining 1263 patients diagnosed between
1990 and 2001 were analyzed.
The date of last visit was used as the end date in Cox and
Kaplan Meier analyses. In case the patient had passed
away, the respondent or member of the family was asked
to provide us with the date of death.
Study variables
Variables were collected using a questionnaire which
included: Sociodemographic data, past medical history
and risk factors, pathologic characteristics and treatment
details. Sociodemographic data collected included the
age, residence, marital status. Past medical history
included coronary artery disease, hypertension, diabetes
and other malignancies. Risk factors included were age at
menarche and menopause, family history of breast cancer,
parity, living children, age at first conception, exposure to
hormonal therapy as oral contraceptive pills (OCP) in
premenopausal women or hormone replacement therapy
(HRT) in postmenopausal women, and benign or low risk
breast lesions. Pathologic data included information on
tumor histology, size, grade, receptor status and axillary
lymph nodes. Hormonal receptors were determined by
immunohistochemistry and were considered positive
when either the ER, PgR or both were positive. Hormone
receptors were considered negative when concentration
was below 10%.
Treatment data included type and duration of neo-adju-
vant therapy, breast-conserving surgery or mastectomy,
adjuvant chemotherapy, radiation therapy and hormonal
therapy with tamoxifen which is given after chemother-
apy. Follow-up data included information about local
and distant sites of recurrences. Dates and causes of death
of deceased patients were recorded.
Statistical methods
The patients were divided into three age groups: patients
less than 35  years of age (Group 1), patients between 35
and 49 years of age (Group 2),  and patients above 50
years of age (Group 3).
The data was analyzed using SPSS v.13.0 and STATA 7.0.
Frequencies of all the variables in question were calcu-
lated. Univariate analysis includes frequencies, and bivar-
iate analysis includes crosstabs (chi square) and t-test. In
the multivariate analysis, Cox regression was used to esti-
mate predictors of shorter survival using the backward
method for insignificant variables elimination with a
removal criteria at less than 0.1. Variables that are consid-
ered in this regression were age, presence of positive
lymph nodes (LNs), grade and size of tumor, hormonal
status, adjuvant chemoradiation and hormonal therapy.BMC Cancer 2006, 6:194 http://www.biomedcentral.com/1471-2407/6/194
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Kaplan Meier curves were used to estimate time-to-death;
in this case the log-rank was used to compare different
groups. P < 0.05 was considered significant in all analysis.
Results
Mean age at presentation was 50.8 ± 12.2 years. 56% of
the patients were postmenopausal. The distribution of
patients by age categories was as follows: 107 patients
(8.1%) were less than 35 years of age, 526 patients
(39.9%) were between 35 and 49 and 687 patients (52%)
were aged 50 years and above.
Patients came from all over the country. 49.3 % (507
patients) were residents of the capital city Beirut. 7.5%
from North Lebanon, 14.5% from South Lebanon, 5.9%
from Bekaa region, and 20.5% from Mount Lebanon
region. This distribution is similar to the population dis-
tribution in the country. Only 2.2% of the patients came
from outside Lebanon.
238 patients (18.3%) had a family history of breast can-
cer. 87.5% were married with children. 12.5% never mar-
ried and never had any children.
197 patients (15.4%) had a history of hypertension and
91 patients (7.1%) had diabetes. 342 patients (34%) had
a history of smoking.
Stage distribution of the tumors was as follows: Stage I:
14.4%, stage II: 59.9%, stage III: 20.0%, and stage IV:
5.7%.
The median follow up time was 2.9 years.
Clinical characteristics and treatment details
The clinical and pathological characteristics, status, and
adjuvant chemotherapy of all patients grouped as <35
years (group 1), between 35–50 years (group 2) and >50
years (group 3) are summarized in table 1.
The three age-groups considered were comparable as far as
the distribution of stage, tumor size and lymph node pos-
itive status Past medical history (including diabetes, CAD,
and HTN) and family history of breast cancer were also
similar across the three age groups mentioned.
68.6% of the young group (Group 1) had positive lymph
nodes, as compared to 66.7% and 61.6% for groups 2 and
3 respectively. This difference was not significant (P value:
0.131).
On the other hand, hormonal receptors, grade and adju-
vant chemotherapy were statistically different across the
mentioned age groups. Table 1 shows that 78.5% patients
who are older than 50 have positive hormonal receptors,
followed by 71.6% of those who are less than 35 years of
age, and finally 67.6% of the intermediate group.
Table 1: Clinical and pathological characteristics, hormonal receptor status, stages, and adjuvant chemotherapy of all patients grouped 
as <35 years (group 1), between 35–50 years (group 2) and >50 years (group 3).
Variable Group1 = <35 Group2 = 35–49 Group3 = >50 Total P value
Tumor size<2 cm 16 (15.7%) 95 (20.0%) 115 (18.8%) 1191 0.877
Tumor 2–5 cm 70 (68.6%) 315 (66.1%) 407 (66.4%)
> 5 cm 16 (15.7%) 66 (13.9%) 91 (14.8%)
Lymph Node Positive 70 (68.6%) 317 (66.7%) 378 (61.6 %) 1191 0.131
Positive hormone Receptors (estrogen and/or 
progesterone)
73 (71.6%) 321 (67.6%) 482 (78.5%) 876/1191 <0.001
Grade I 5 (4.9%) 49 (10.3%) 79 (12.9%) 1191 0.019
Grade II 47 (46.1%) 226 (47.6%) 315 (51.3%)
Grade III 50 (49%) 200 (42.1%) 220 (35.8%)
Stage I 12 (11.2%) 74 (14.8%) 96 (14.6%) 182 (14.4%) 0.619
Stage II 63 (58.9%) 305 (61.1%) 389 (59.1%) 757 (59.9%)
Stage III 27 (25.2%) 96 (19.2%) 129 (19.7%) 252 (20.0%)
Stage IV** 5 (4.7%) 24 (4.8%) 44 (6.6%) 72 (5.7%)
Adjuvant Chemotherapy 78 (76.5%) 346 (72.8%) 326 (53.1%) 750/1191 <0.001
Adjuvant Anthracycline* 42 (56.0%) 228 (68.3%) 163 (50.6%) 443/731 <0.001
Development of metastasis 33 (32.4%) 109 (22.9%) 140 (22.8%) 282/1191 0.098BMC Cancer 2006, 6:194 http://www.biomedcentral.com/1471-2407/6/194
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There was a significant difference in the grade between the
three groups. The grade was worse as the age at presenta-
tion decreased (P = 0.019). In fact, Grade III tumours con-
stituted 49%, 42.1% and 35.8% of cases for patients <35,
35–50 and >50 years of age respectively.
Adjuvant chemotherapy was given to 76.5% and 72.8% of
group 1 and group 2 respectively, while only to 53.1% of
the older age group (P < 0.001). As for the type of chemo-
therapy, more anthracycline-based regimens were given to
patients who were between 35 and 50 years old in 68.3%
of the cases, and to only 56% in group 1 patients and
50.6% in group 3 patients (P < 0.001). This suggested that
young patients were treated more aggressively than their
older counterparts.
Adjuvant hormonal therapy was given to patients with
positive hormone receptor in the three age groups were as
follows: 62 patients of 74 (83.8%) aged less than 35
received adjuvant tamoxifen, 287 patients of 327
(87.76%) ages: 35–50 received tamoxifen, and 455
patients of 499 (91.2%) aged above 50 years received
adjuvant tamoxifen. It was equivalent in the three age
groups (P = 0.081: not significant). Patients reported in
this series were seen before the results of adjuvant trials
with aromatase inhibitors were published and all patients
were treated with adjuvant tamoxifen. The survival in the
young age group of women was worse in spite of the hor-
monal treatment
Higher proportion of patients in the youngest group
develops metastasis after diagnosis; 32.4% compared to
22.9% and 22.8% for groups 1 and 2 respectively. How-
ever, p value of 0.098 suggests an insignificant difference
in these proportions.
Effects of various prognostic factors on survival in non-
metastatic patients
Table 2 shows the results of the Cox regression analysis.
This analysis was done to assess the variables that contrib-
ute most to the duration of survival. Patients who had
Stage IV at presentation were removed from this table.
1- Effect of tumor grade
Tumor grade is a significant prognostic factor for survival;
grade II and grade III patients are 1.813 and 2.161 times
more likely to have a shorter survival than grade I patients.
P value was most significant for Grade III patients.
2- Effect of positive hormonal receptors
Table 2 shows that patients with negative hormonal recep-
tors are 65% less likely to survive than the group with pos-
itive hormonal receptors. As mentioned earlier, The
distribution of adjuvant hormonal treatment in hormone
receptor positive patients in the three age groups. was
equivalent (P = 0.081). The survival in the young age
group of women was worse in spite of the hormonal treat-
ment
3- Effect of tumor size
Tumor size played a major role in predicting survival.
While those who have T2 lesions (2–5 cm) have 2.003
higher chance or shorter survival, patients with T3 lesions
(>5 cm) reach a remarkable 3.099 higher risk of death
than T1 (<2 cm) lesions patient with a 95% CI that reaches
5.89 times the risk of a T1 patient.
4- Effect of positive lymph nodes
The presence of positive LNs had a more adverse effect on
survival for the youngest group than for the other two
groups. Lymph node positivity was inversely proportional
to survival in our population (p < 0.001). In fact those
Table 2: Effects of various prognostic factors on survival: Cox Regression analysis of effects of tumor grade, positive hormonal 
receptors, tumor size and age on survival for non-metastatic patients. Patients with grade III had a significant higher risk of death (p 
0.039) as compared to the reference grade I. Hormone receptor negativity conveys a significantly higher risk for death (p value 0.003). 
Larger tumor sizes and lymph node positivity correlated with significantly higher risks for death. Patients below 35 have the highest 
risk of death as compared to patients age 35–50 and those above 50 years. Other variables including adjuvant chemoradiation and 
hormonal therapy were not found to be significant.
Variable P value Hazard Ratio 95% CI for hazard ratio
Grade I 0.097 1.000
Grade II 0.113 1.813 0.87 – 3.78
Grade III 0.039 2.161 1.04 – 4.49
Negative hormonal receptors 0.003 1.654 1.18 – 2.32
Tumor size < 2 cm 0.002 1.000
Tumor size 2 cm – 5 cm 0.020 2.003 1.12 – 3.59
Tumor size >5 cm 0.001 3.099 1.63 – 5.89
Presence of positive Lymph Nodes <0.0001 2.370 1.54 – 3.64
Age less than 35 0.015 1.000
Age between 35–49 0.005 0.476 0.28 – 0.80
Age 50 and above 0.086 0.651 0.40 – 1.06BMC Cancer 2006, 6:194 http://www.biomedcentral.com/1471-2407/6/194
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who have lymph node invasion are 2.370 times more
likely to die, controlling for the rest of the variables.
5- Effect of age
The best survival was noted for the middle group that
includes patients 35–49 years, followed by those who are
>50 years, and the worst survival was found in the young-
est group (Figure 1). When we stratified patients by age
groups: Group 1 (<35), Group 2 (35–50) and Group 3
(>50), survival was significantly worse for the youngest
group with P = 0.03. Age impacted other variables if
patients were stratified by the mentioned age groups.
Patients with positive receptors were stratified by age and
the Kaplan Meier analysis showed that the youngest group
is at a disadvantage P = 0.024. Among patients with posi-
tive LNs, those who are younger than 35 have worse sur-
vival, P = 0.021.
Effects of age according to Lymph node status: We looked
at the effects of young age in patients with positive lymph
nodes versus negative lymph nodes, and patients with
positive hormonal receptors versus negative hormonal
receptors in the three different age groups below 35 years
(group 1), between 35–50 (group 2) and above 50 (group
3). For patients with positive lymph nodes, age was a sig-
nificant prognostic factor (Figure 2).
For groups with negative LN, there was no impact on sur-
vival. The numbers of patients in the Kaplan Meier graph
were as follows: Total number was 426 patients, 32
patients in group below 35 years, 158 patients in group
35–50 years, and 236 in group >50 years; and the number
of events were 2, 11, and 14 in each of the age groups
respectively. The survival curves for each of those sub-
groups did not differ significantly (Figure 3)
Effects of age according to hormonal receptors status:
Analysis of the three different age groups for patients with
positive hormonal receptors showed the following num-
bers: 72 patients in group 1, 320 patients in group 2 and
481 patients in group 3. The total was 873 patients. We
plotted survival curves and age was a significant prognos-
Kaplan-Meier survival analysis of patients with negative lymph  nodes and effects on survival stratified by age groups below  35 years, between 35–50 years, and above 50 years Figure 3
Kaplan-Meier survival analysis of patients with negative axil-
lary lymph nodes and effects on survival stratified by age 
groups below 35 years, between 35-50 years, and above 50 
years. Age had no effect on survival in groups with negative 
axillary lymph nodes (P=0.960).
Stratified analysis of survival of breast cancer between three  age groups (below 35, 35–50, and above 50): Patients with  primary breast cancer below the age of 35 had a worse sur- vival than the group 35–50 and group above age 50 Figure 1
Stratified analysis of survival of breast cancer between three 
age groups (below 35, 35-50, and above 50): Patients with 
primary breast cancer below the age of 35 had a worse sur-
vival than the group 35-50 and group above age 50. The p-
value of 0.03 shows that young age at presentation disadvan-
tages survival.
Kaplan-Meier survival analysis of patients with positive lymph  node and effects on survival stratified by age groups below 35  years, between 35–50 years, and above 50 years Figure 2
Kaplan-Meier survival analysis of patients with positive axil-
lary lymph nodes and effects on survival stratified by age 
groups below 35 years, between 35-50 years, and above 50 
years. Patients with positive axillary lymph nodes and young 
age have worst survival. (P=0.021).BMC Cancer 2006, 6:194 http://www.biomedcentral.com/1471-2407/6/194
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tic factor (Figure 4). Analysis the three different age groups
for patients with negative hormonal receptors showed the
following numbers of patients in each age category in the
Kaplan Meier: Total number of patients was 315 patients,
below 35 years: 29 patients, between 35–50 years: 154
patients, and above 50 years there were 132 patients. We
plotted survival graphs and there were no statistically sig-
nificant difference in subgroups of patients with negative
hormonal receptors (Fig 5).
Discussion
Young age at diagnosis of breast cancer has been reported
in many studies from the US and Europe to be an inde-
pendent predictor of worse survival[4,6-9,11]. The risk
factor profile of young patients is worse than their older
counterparts. Young patients tend to have larger tumor
sizes, more positive lymph nodes, more negative hor-
mone receptors, higher tumor grades than their older
counterparts[9,10,17-19]. The issue remains controversial
and not all studies reported age as an adverse prognostic
factor[10-13,17,18]. Few reports from developing coun-
tries such as from Saudi Arabia found that young age did
not have an adverse effect on survival of breast cancer
patients[12]. Chia et al, in a retrospective study of breast
cancer patients, from Singapore, demonstrated that young
females with breast cancer had a better survival than older
females[13]. The recently reported population-based
study from Switzerland showed no effect of young age on
survival but authors had only 3% of their patients below
age 35, 26% 35–50 and 71% above 50. This small number
of very young patients may have affected statistical power
of study. Authors concluded that when standard care is
offered to young patients, their prognosis is not worse
than their older counterparts[11].
Our results show that young age is a bad prognostic factor
in women with breast cancer in Lebanon. The distribution
of the various prognostic factors, except estrogen receptor
positivity, and grade did not differ significantly in the
three age groups in our patient population. A higher than
expected percentage of receptor positivity was noted; this
correlates with recent reports from other neighbouring
countries and the USA[20,21]. Recent Surveillance Epide-
miology and End Results (SEER) data indicated a 20%
increase in the incidence of ER positive tumors between
1992 and 1998[20]. Similar increased percentage of
higher estrogen receptor positivity in breast cancer was
reported as well from Israel[6] and Kuwait[21]. Although
our patients had an increased rate of positive receptors
and received more aggressive chemotherapy than older
patients, they still had a worse survival.
Although group 3 of older patients had significantly more
hypertension (HTN), diabetes (DM) and cardiac diseases
(CAD) (P < 0.001), no effect of co-morbid illnesses (CAD,
DM, and HTN) were detected in the three age groups.
Velanovich et al [22] reported that older patients with
breast cancer are usually undertreated because of co-mor-
bid conditions (40.9%), or for refusal of treatment
(31.8%), or favourable tumor pathology (13.8%) or
unexplainable causes (13.6%). In our population, 53.1%
of patients over 50 years of age received chemotherapy, as
compared to 76.5% and 72.8% in the younger groups 1
and 2 respectively.
Kaplan-Meier survival analysis of patients with negative hor- mone receptors and effects on survival stratified by age  groups below 35 years, between 35–50 years, and above 50  years Figure 5
Kaplan-Meier survival analysis of patients with negative hor-
monal receptors and effects on survival stratified by age 
groups below 35 years, between 35-50 years, and above 50 
years. Age had no effect on survival in groups of patients with 
negative hormonal receptors (P: 0.481).
Kaplan-Meier survival analysis of patients with positive hor- monal receptors and effects on survival stratified by age  groups below 35 years, between 35–50 years, and above 50  years Figure 4
Kaplan-Meier survival analysis of patients with positive hor-
monal receptors and effects on survival stratified by age 
groups below 35 years, between 35-50 years, and above 50 
years. Survival is worst in younger-aged patients with positive 
hormonal receptors (P=0.024).BMC Cancer 2006, 6:194 http://www.biomedcentral.com/1471-2407/6/194
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Overall data shows that young age is a significant prog-
nostic factor for survival of patients with primary breast
cancer. We looked at subgroups of patients with negative
vs positive Lymph nodes and patients with negative vs.
positive hormonal receptors and had different results.
Young age had a significant impact on survival in patients
with positive lymph nodes but not in patients with nega-
tive lymph nodes. Young age had a significant impact on
survival in patients with positive receptors but not nega-
tive receptors. Grade and vascular invasion were signifi-
cantly worse in group 2 (between 35–50 years) with
positive LN vs. negative LN, and in group 3 (>50 years)
there were significantly more vascular invasion in node
positive versus node negative patients. The analysis of
subgroups, in efforts to explain the differences, remains
unresolved and requires further investigation.
Conclusion
In conclusion, we report that young age is an independent
adverse prognostic factor in younger patients with breast
cancer. Younger patients had a percentage of positive hor-
mone receptors that is higher than expected, but similar to
recent trends reported in the literature. Younger patients
received more anthracycline-based adjuvant chemother-
apy. Survival in young patients was worse inspite the fact
that they also received adjuvant hormonal therapy with
tamoxifen. Young age at presentation remained a bad
prognostic factor in patients with breast cancer. This neg-
ative impact on survival was seen in patients with positive
lymph nodes and those with positive hormonal receptors.
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